FDA Laws & Pharmacy Practice

Tom Hazlet
Pharmacy 543
Autumn 2005

Objectives

- Be able to discuss the evolution of food and drug law in the United States
- Be able to discuss the ways in which pharmacists and other health care practitioners may violate these laws
- Be able to explain the significance of "adulterated" and "misbranded" in the context of pharmacy practice
- Be able to describe
  - the use of the "Orange Book" and its significance in pharmacy practice in Washington
  - expiration date meaning
  - National Drug Code and its utility
  - FDA "voluntary" recalls

History Review

- Review Pharmacy 309 Notes (posted on web site)
- Review Chapters 2 & 3 in Abood – optional
- Check out FDA web site
  - www.fda.gov
  - Do Drugs, Biologics; look over “From Test Tube to Patient”, etc.

Food, Drug & Cosmetic Act, as amended

- Statutory authority (Title 21 United States Code) to promulgate regulations (Title 21 Code of Federal Regulations)
  - Laws Enforced by FDA
- Centers for
  - Drug Evaluation & Research (CDER)
  - Biologics Evaluation & Research (CBER)
  - Devices & Radiological Health (CDRH)
  - Food Safety & Applied Nutrition (CFSAN)
  - Veterinary Medicine (CVM)
What makes a drug a “drug”

CDER

- 4 things
  - recognized in an “official compendium”
    - USP / NF
    - Homeopathic Pharmacopeia of the United States
  - intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals
  - intended to affect the structure or function of the body of man or other animals, but not food
  - components

section 201(g)(1)

device

CDRH

- Same as “drug”, except
  “... does not achieve any of its principal intended purposes through chemical action ... and is not dependent upon being metabolized ....”

cosmetic

CFSAN

- Intended to be [applied, smeared, squished about ...] for cleaning, beautifying, promoting attractiveness, altering appearance
- components
- not soap
- man or any other beast?

food

CFSAN

- ... used for food or drink for man or other animals
- components
- cf. dietary supplements;
  - DSHEA – Dietary Supplement & Health Education Act
  - Proxmire Amendment
biologic

CBER

- Parallel evolution -- Public Health Service
- any virus, therapeutic serum, toxin, antitoxin, or analogous product applicable to the prevention, treatment or cure of diseases or injuries of man; “biotechnology-derived therapeutic”
- big administrative differences; some similarities
- “cats marching ...”; and again; transfer of “well characterized biologicals” to CDER

Durham-Humphrey Amendment & Prescription Drugs, etc.

- Intended for use by man, and
  - is a habit-forming drug, or
  - because of its toxicity or other potentiality for harmful effect ... method of use ... collateral measures necessary to its use
- is not safe except under the supervision of a practitioner licensed to administer ...

DH2

- Limited by an approved application
- violations → “misbranded”
- exemption from § 502 requirements
- requirement for federal “Caution” [legend]

FD&C Act’s 2 big sticks

- Adulteration
- Misbranding

- Penalties: hate mail (including a “warning letter”), seizure, injunction, fine, criminal prosecution
Thou shalt not -- prohibitions

- “Introduce” or deliver into interstate commerce any [stuff] that is adulterated or misbranded
- adulterate or misbrand
- “receive” stuff that’s A’d or M’d
- refuse to permit inspection by an authorized person
- counterfeit (placebo?)
- alter labeling in a way that would result in the product being A’d or M’d

Adulteration

- Made from bad stuff (“filthy, putrid …”)
- made in a place or way that could result in (“whereby”) A
- container/closure system could permit A
- strength/quality differs from claim; official compendium or otherwise
- parrot in the pharmacy ...
- note burden of proof

A-word 2

- Current Good Manufacturing Practices
- International Commission on Harmonisation
- Product tampering; tamper resistant packaging

21 CFR Part 1.3 Definitions

(a) Labeling includes all written, printed, or graphic matter accompanying an article at any time while such article is in interstate commerce or held for sale after shipment or delivery in interstate commerce.

(b) Label means any display of written, printed, or graphic matter on the immediate container of any article, or any such matter affixed to any consumer commodity or affixed to or appearing upon a package containing any consumer commodity.
Misbranding

- “Labeling” is false or misleading in any particular
- place of business (manufacturer, packer or distributor)
- understandability by ordinary person under customary conditions of purchase/use
- warning for habit-forming

M-word 2

- Size of type
- active ingredients specified; inactives in (descending order of predominance) alpha order; alcohol
- established name (USAN – United States Adopted Names)
- adequate directions for use & warnings
- packaging per compendial standards
- misleading packaging; imitation

M-word 3

- Following labeling could result in health hazard
- if subject to deterioration; packaging, precautions in labeling
- adequate information for use (MedGuide)

Other FDA - Pharmacy Practice Items

- Orange Book
- Expiration Dates
- Recalls
- NDC
Orange Book

- ... some inconvenient terminology
- "therapeutic equivalence" vs. "generic substitution", "therapeutic interchange" (aka therapeutic substitution)
- Electronic Orange Book -- Approved Products with Therapeutic Equivalence Evaluations

OB3

- **WAC 246-899-030 Product selection responsibilities.**
  - (1) The determination of the drug product to be dispensed on a prescription is a professional responsibility of the pharmacist, and the pharmacist shall not dispense any product that in his/her professional opinion does not meet adequate standards.
  - (2) Pharmacists may utilize as the basis for their decisions on therapeutically equivalent drug products:
    - (a) Available drug product information from federal and state agencies, official compendia, and drug manufacturers, or
    - (b) Other scientific or professional resources, or
    - (c) The federal food and drug administration "approved drug products" as a board approved reference for a positive formulary of therapeutically equivalent products within the limitations stipulated in that publication.

OB4

- Importance of definitions
- RCW 69.41.110 Definitions. As used in RCW 69.41.100 through 69.41.180, the following words shall have the following meanings:
  - (3) "Substitute" means to dispense, with the practitioner's authorization, a "therapeutically equivalent" drug product of the identical base or salt as the specific drug product prescribed: PROVIDED, That with the practitioner's prior consent, therapeutically equivalent drugs other than the identical base or salt may be dispensed;
  - (4) "Therapeutically equivalent" means essentially the same efficacy and toxicity when administered to an individual in the same dosage regimen;

Expiration Date

- All OTC and prescription drugs have expiration dates, but ...
- Drug expires on ... the last day of the month
- Misbranding to sell after expiration
- Watch computer assignment of expiration date; patient confusion when pharmacy and printed label differ
cGMP regulations, drug products are labeled with an expiration date determined by appropriate stability testing (21CFR211.137 and 166) ... evaluated over time, in same container-closure system, conditions of storage, transportation accelerated stability studies to support tentative expiration dates; firm liability new studies required for packaging changes

USFDA Compliance Policy Guide CPG 7132.10 Lack of expiration date of stability data

21CFR137 Expiration Dating (excerpts)
(e) Homeopathic drug products are exempt
(f) Allergenic extracts that are labeled “No U.S. Standard of Potency” are exempt
(g) New drug products for investigational use are exempt ... provided that they meet appropriate standards ...
(h) Pending consideration of a proposed exemption, published in the Federal Register of September 29, 1978, the requirements in this section shall not be enforced for human OTC drug products if their labeling does not bear dosage limitations and they are stable for at least 3 years as supported by appropriate stability data.

“FDA” Recalls
Product is subject to FDA legal action
- threat or potential threat to humans or animals
  - adulteration
  - misbranding
  - materially misleading (fraud/deception)
- Voluntary, NOT government action
- FDA can only get injunctions or seizures

Types of Recalls
- Class I - use or exposure can cause serious health consequences or death
- Class II - use may cause temporary medically reversible health consequences
- Class III - use not likely to cause adverse health consequences
Levels of Recalls

- 1 consumer or patient level (pharmacy cooperation in identifying patients)
- 2 retail level
- 3 wholesale level

Recalls 3

- Where do you hear about recalls?
  - news media (FDA media release); FDA listserv
  - Manufacturer / wholesaler
  - National publications (i.e., ASHP Newsletter)
  - Pharmacy “hot lines”

Drug and Device Listing and Establishment Registration

- FD&C Act and FDA regulations require registration of establishments and products in 4 major categories:
  - “low acid” canned foods
  - acidified foods
  - drugs
  - medical devices
- Failure to register facility a crime and renders the products misbranded
- Cosmetic firms (formulas) may register voluntarily

FDA Registration 2

- Applicable to **bulk** and **finished** dosage forms, and to imported and exported commodities
- Establishment registration must be updated annually
- Product listings updated January & June, if material changes have occurred
National Drug Code (NDC)

- 21CFR207.35(b)(3) FDA requests but does not require that the NDC number appear on all drug labels and in other drug labeling, including the label of any prescription drug container furnished to a consumer.
- The NDC is one of the following configurations: 4-4-2, 5-3-2, or 5-4-1: labeler, product, packaging
- 10 vs. 11 digits ....
- Who cares?

NDC Examples

- “Labeler” code
  - 0002 ELI LILLY AND CO

- “Labeler”, “product” and “package” code
  - STRATTERA CAPSULES 18MG 0002 - 3238 - 01 BLPK 1 X 4
  - STRATTERA CAPSULES 18MG 0002 - 3238 - 07 BOT 1 X 7
  - STRATTERA CAPSULES 18MG 0002 - 3238 - 30 BOT 30

More NDC Examples

<table>
<thead>
<tr>
<th>Labeler Code Firm Name</th>
<th>Trade Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>54868 PHYSICIANS TOTAL CARE INC</td>
<td>ACCOLATE TABLETS 20MG</td>
<td></td>
</tr>
<tr>
<td>54868 PHYSICIANS TOTAL CARE INC</td>
<td>ACCUPRIL TABLETS 5MG</td>
<td></td>
</tr>
<tr>
<td>54868 PHYSICIANS TOTAL CARE INC</td>
<td>ACCUPRIL TABLETS 40MG</td>
<td></td>
</tr>
<tr>
<td>54868 PHYSICIANS TOTAL CARE INC</td>
<td>ACCUPRIL TABLETS 10MG</td>
<td></td>
</tr>
<tr>
<td>54868 PHYSICIANS TOTAL CARE INC</td>
<td>ACCUPRIL TABLETS 20MG</td>
<td></td>
</tr>
<tr>
<td>54868 PHYSICIANS TOTAL CARE INC</td>
<td>ACUTANE CAPSULES 40MG</td>
<td></td>
</tr>
<tr>
<td>54868 PHYSICIANS TOTAL CARE INC</td>
<td>PHOSPHATE SOLUTION COMBO</td>
<td></td>
</tr>
<tr>
<td>54868 PHYSICIANS TOTAL CARE INC</td>
<td>ACETAMINOPHEN AND CODEINE</td>
<td></td>
</tr>
</tbody>
</table>

Summing Up

- What makes a drug a drug
- What is FDA’s jurisdiction
- Distinguish between adulteration and misbranding
- Expiration dates
- FDA registration
- Recalls
- NDC